

Dunston 10/091,177

12/16/2005

=> d his full

(FILE 'HOME' ENTERED AT 09:39:41 ON 16 DEC 2005)

L1 FILE 'LREGISTRY' ENTERED AT 09:44:54 ON 16 DEC 2005  
STRUCTURE

L2 FILE 'REGISTRY' ENTERED AT 10:02:16 ON 16 DEC 2005  
0 SEA SSS SAM L1  
D QUE STAT  
L3 STRUCTURE

L4 FILE 'REGISTRY' ENTERED AT 10:08:08 ON 16 DEC 2005  
0 SEA SSS SAM L3  
L5 STRUCTURE  
L6 0 SEA SSS SAM L5  
L7 1 SEA SSS FUL L5  
D SCAN

L8 FILE 'BEILSTEIN' ENTERED AT 10:12:19 ON 16 DEC 2005  
0 SEA SSS SAM L5  
L9 0 SEA SSS FUL L5

L10 FILE 'MARPAT' ENTERED AT 10:13:04 ON 16 DEC 2005  
0 SEA SSS SAM L5  
L11 0 SEA SSS FUL L5

L12 FILE 'HCAPLUS' ENTERED AT 10:17:26 ON 16 DEC 2005  
5 SEA ABB=ON PLU=ON L7

L13 FILE 'CAOLD' ENTERED AT 10:17:47 ON 16 DEC 2005  
0 SEA ABB=ON PLU=ON L7

FILE 'REGISTRY' ENTERED AT 10:18:24 ON 16 DEC 2005  
D L7 LC

FILE 'CAOLD' ENTERED AT 10:18:24 ON 16 DEC 2005

L14 FILE 'USPATFULL, USPAT2' ENTERED AT 10:19:49 ON 16 DEC 2005  
7 SEA ABB=ON PLU=ON L7

L15 FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 10:20:55 ON 16 DEC 2005  
9 DUP REM L12 L14 (3 DUPLICATES REMOVED)  
ANSWERS '1-5' FROM FILE HCAPLUS  
ANSWERS '6-9' FROM FILE USPATFULL

FILE HOME

FILE LREGISTRY  
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE REGISTRY  
Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 DEC 2005 HIGHEST RN 870070-25-0

DICTIONARY FILE UPDATES: 15 DEC 2005 HIGHEST RN 870070-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE BEILSTEIN  
FILE LAST UPDATED ON OCTOBER 10, 2005

FILE COVERS 1771 TO 2005.

FILE CONTAINS 9,363,954 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

NEW  
\* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE  
SEARCHED, SELECTED AND TRANSFERRED.  
\* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,

**ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

FILE MARPAT

FILE CONTENT: 1988-PRESENT (VOL 143 ISS 24) (20051211/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6943267 13 SEP 2005  
DE 1020040544 15 SEP 2005  
EP 1577935 21 SEP 2005  
JP 2005272454 06 OCT 2005  
WO 2005097137 20 OCT 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

MARPATpreviews will be removed from STN on December 31, 2005.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Dec 2005 VOL 143 ISS 26  
FILE LAST UPDATED: 15 Dec 2005 (20051215/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CAOLD

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Dec 2005 (20051215/PD)  
FILE LAST UPDATED: 15 Dec 2005 (20051215/ED)  
HIGHEST GRANTED PATENT NUMBER: US6976271  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005278816  
CA INDEXING IS CURRENT THROUGH 15 Dec 2005 (20051215/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Dec 2005 (20051215/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

#### FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 15 Dec 2005 (20051215/PD)  
FILE LAST UPDATED: 15 Dec 2005 (20051215/ED)  
HIGHEST GRANTED PATENT NUMBER: US2004010853  
HIGHEST APPLICATION PUBLICATION NUMBER: US2005278014  
CA INDEXING IS CURRENT THROUGH 15 Dec 2005 (20051215/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Dec 2005 (20051215/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text of the latest US publications, starting in 2001, for the inventions covered in USPATFULL. USPATFULL contains full text of the original published US patents from 1971 to date and the original applications from 2001. In addition, a USPATFULL record for an invention contains a complete list of publications that may be searched in standard search fields, e.g., /PN, /PK, etc.


USPATFULL and USPAT2 can be accessed and searched together through the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees, classifications, or claims, that may potentially change from the earliest to the latest publication.

=> d que stat 115

L5

STR



VPA 17-12/13/14 U

## NODE ATTRIBUTES:

```

CONNECT IS E2 RC AT 10
CONNECT IS E1 RC AT 21
CONNECT IS E1 RC AT 23
DEFAULT MLEVEL IS ATOM
GGCAT IS LOC AT 10
GGCAT IS LOC AT 18
GGCAT IS LOC AT 23
GGCAT IS MCY UNS AT 24
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 24

```

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L7 1 SEA FILE=REGISTRY SSS FUL L5  
L12 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L7  
L14 7 SEA L7  
L15 9 DUP REM L12 L14 (3 DUPLICATES REMOVED)

=> d 115 ibib abs hitstr 1-9



L15 ANSWER 1 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1  
ACCESSION NUMBER: 2005:2193 HCPLUS  
DOCUMENT NUMBER: 142:51353  
TITLE: Pyrazole derivative inhibitors of cyclin-dependent  
kinases for use as antitumor and antiviral agents  
INVENTOR(S): Becker, Frank; Bockovich, Nicholas; Come, Jon H.;  
Kluge, Arthur; Murthi, Krishna K.; Oalmann, Chris;  
Ram, Siya; Wang, Zhongguo  
PATENT ASSIGNEE(S): GPC Biotech, Inc., USA; GPC Biotech A.-G.  
SOURCE: U.S. Pat. Appl. Publ., 103 pp., Cont.-in-part of Appl.  
No. PCT/US02/33052.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

Dunston 10/091,177

12/16/2005

US	2004266854	A1	20041230	US	2004-820453	20040407
WO	2002070662	A2	20020912	WO	2002-US6677	20020304
WO	2002070662	A3	20021227			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US	2003165873	A1	20030904	US	2002-91177	20020304
US	2004043388	A1	20040304	US	2002-234985	20020903
WO	2003033499	A2	20030424	WO	2002-US33052	20021015
WO	2003033499	A3	20030814			
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
PRIORITY APPLN. INFO.:				US	2001-272932P	P 20010302
				US	2001-329437P	P 20011015
				US	2001-336962P	P 20011203
				US	2002-91177	A2 20020304
				WO	2002-US6677	A2 20020304
				US	2002-234985	A2 20020903
				WO	2002-US33052	A2 20021015
				US	2003-460921P	P 20030407
				US	2003-531872P	P 20031223
				US	2001-278233P	P 20010323

OTHER SOURCE(S) : MARPAT 142:51353  
GI




AB Title compds. I [B = MnR8; Ar = aryl, heteroaryl; V = O, S, NCN; W = O, S, N-R'; R' = H, lower alkyl, metal counterion; R5 = H, P(O)(OR')2, MnQ; R6 = H, OH, MnQ, provided that one and only one of R5 and R6 = H; R7 = H, halo, OH, lower alkyl, lower alkoxy; R8 = (un)substituted-alkyl, -alkenyl, -aryl, etc.; M = (un)substituted methylene, O, S, etc., where n = 1-4 when present in B, 0-6 when present in R5, and 1-3 when present in R6; Q = (un)substituted tertiary amino substituent, N-containing heterocycle] and II [X = Me, halo; Y = H, X, sulfonamide; R1 = H, P(O)(OR')2, MnQ; R3 = 0-3 substituents on the ring to which it is attached, selected from halo, alkyl, alkoxy, etc.; Ar and W as in I], as well as their pharmaceutically acceptable salts, are prepared and disclosed as novel cyclin dependent kinase (cdk) inhibitors. Thus, e.g., III.2HCl was prepared via substitution of N-morpholin-4-yl(4-nitrophenoxy)carboxamide (preparation given) with 4-amino-2-{4-(5,5-dimethyl-1,3-dioxan-2-yl)phenylcarbonyl}-2H-cyclopent a[1,2-a]benzene-1,3-dione (preparation given) followed by cyclocondensation with hydrazine, deprotection of formyl moiety, amidation with N-(2-methoxyethyl)-piperazine and subsequent reduction. Specifically, but not exclusively, I are disclosed as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. would be useful for treating subjects having disorders associated with excessive cell proliferation, such as cancer. Addnl., the compds. may be useful as antivirals.

IT 452913-20-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents)

RN 452913-20-1 HCPLUS

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl-(9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:182368 HCPLUS  
DOCUMENT NUMBER: 140:229401  
TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands  
INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6

## PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903
US 2003165873	A1	20030904	US 2002-91177	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:				
			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2002-91177	A2 20020304
			US 2001-336962P	P 20011203
			WO 2002-US6677	A2 20020304
			US 2002-234985	A2 20020903
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g. a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.

IT **452913-20-1D**, conjugates  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 452913-20-1 HCPLUS

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

L15 ANSWER 3 OF 9 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:902355 HCPLUS  
 DOCUMENT NUMBER: 141:395546  
 TITLE: Preparation of pyrazole derivatives as inhibitors of cyclin-dependent kinases, compositions and uses related thereto  
 INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur; Oalmann, Chris; Murthi, Krishna K.; Ram, Siya; Wang, Zhongguo; Huang, Jianxing  
 PATENT ASSIGNEE(S): GPC Biotech, Inc., USA  
 SOURCE: PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

6

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092139	A2	20041028	WO 2004-US10381	20040406
WO 2004092139	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521854	AA	20041028	CA 2004-2521854	20040406
US 2004266853	A1	20041230	US 2004-819899	20040406
PRIORITY APPLN. INFO.:			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223
			WO 2004-US10381	W 20040406

OTHER SOURCE(S): MARPAT 141:395546

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [B = MnR8; Ar = aryl or heteroaryl ring; V = O, S, or NCN; W = O, S, SO2 CO, CS, CH2, NH, or N-alkyl; R5 = H, P(O)(OR')2, MnJK, MnQ; R' = H, alkyl, or metal counterion; R6 = H, OH, or MnQ, provided that one and only one of R5 and R6 = H; R7 = H, halo, OH, alkyl, or alkoxy; R8 = (un)substituted-alkyl, -alkenyl, -aryl, etc.; J = CO, CS, or SO2; K = OR', NH, N-alkyl, etc.; M = (un)substituted methylene group, O, S, etc., where n = 1-7 when present in B, 0-6 when present in R5, and 1-3 when present in R6; Q = (un)substituted N-containing heteroaryl ring, secondary or tertiary amino substituent, or N-containing heterocycle] and II [X = Me or halo; Y = H, X, or sulfonamide; R1 = H, P(O)(OR')2, or MnQ; R3 = 0-3 substituents on the ring to which it is attached, selected from halo, alkyl, alkoxy, etc.], as well as their pharmaceutically acceptable salts, are prepared and disclosed as novel cyclin dependent kinase inhibitors (cdks). Thus, e.g., III·2HCl was prepared via substitution of N-morpholin-4-yl(4-nitrophenoxy)carboxamide (preparation given) with 4-amino-2-{4-(5,5-dimethyl-1,3-dioxan-2-yl)phenylcarbonyl}-2H-cyclopenta[1,2-a]benzene-1,3-dione (preparation given) followed by cyclocondensation with hydrazine, deprotection of formyl moiety, amidation with N-(2-methoxyethyl)-piperazine and subsequent reduction. Specifically, but not exclusively, I are disclosed as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compds. would be useful for treating subjects having disorders associated with excessive cell proliferation.

IT 452913-20-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of pyrazole derivs. as inhibitors of  
 cyclin-dependent kinases)

RN 452913-20-1 HCAPLUS

CN Propanoic acid, 2-[4-[(4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)methyl]phenoxy]-2-methyl-(9CI) (CA INDEX NAME)



L15 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:319902 HCAPLUS

DOCUMENT NUMBER: 138:338168

TITLE: Preparation arylalkyl substituted pyrazolo[5,4-d]pyrimidines and related analogs as inhibitors of cyclin-dependent kinases

INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur F.; Ram, Siya; Wang, Zhonghuo; Oalmann, Chris; Murthi, Krishna K.

PATENT ASSIGNEE(S): GPC Biotech Inc., USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033499	A2	20030424	WO 2002-US33052	20021015
WO 2003033499	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463571	AA	20030424	CA 2002-2463571	20021015
EP 1446405	A2	20040818	EP 2002-797047	20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005511535	T2	20050428	JP 2003-536238	20021015
US 2005090471	A1	20050428	US 2003-492116	20021015
US 2003162797	A1	20030828	US 2002-321284	20021217
US 6753329	B2	20040622		

US 2004266854  
PRIORITY APPLN. INFO.:

A1 20041230

US 2004-820453

20040407

US 2001-329437P

P 20011015

US 2001-336962P

P 20011203

US 2001-272932P

P 20010302

US 2002-91177

A2 20020304

WO 2002-US6677

A2 20020304

US 2002-234985

A2 20020903

WO 2002-US33052

W 20021015

US 2003-460921P



P 20030407

US 2003-531872P

P 20031223

OTHER SOURCE(S):  
GI

MARPAT 138:338168



AB Title compds. I [W = O; NR'; X = halo, F, Cl, Br, I; Y = H, X; R1 = H, PO(OR')2, MnQ; R2 = H, MnQ, provided that one and only one of R1/R2 = H; M = CH2, O, SOO-2, etc.; n = 1-5; Q = tertiary amino] are prepared For instance, (1-chloro-2-methylpropylidene)methane-1,1-dicarbonitrile (preparation given) is reacted with 2,6-dichlorophenylhydrazine•HCl (THF, Et3N, reflux, 18 h) to give 5-amino-1-(2,6-dichlorophenyl)-3-isopropyl-1H-pyrazole-4-carbonitrile. This intermediate is converted to the corresponding amide (H2SO4) and reacted with Et 4-hydroxyphenylacetate (EtOH, NaOEt) resulting in the formation of the corresponding pyrazolo[3,4-d]pyrimidin-4-one intermediate. This was derivatized with di-(tert-butyl) N,N-diisopropylphosphoramidite (DMF, tetrazole, 3 h), the resulting intermediate treated with mCPBA and finally deprotected (TFA) to give II. Compds. of the invention were tested for activity against cyclin dependent kinases, e.g., Cdk2/cyclin E, Cdk4/cyclin D1, etc. I are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell


growth and differentiation. Such compds. are useful for treating subjects having disorders associated with excessive cell proliferation.

IT 452913-20-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation arylalkyl substituted pyrazolo[5,4-d]pyrimidines and indeno[1,2-c]pyrazoles as inhibitors of cyclin-dependent kinases)

RN 452913-20-1 HCAPLUS

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:696096 HCAPLUS

DOCUMENT NUMBER: 137:197882

TITLE: Three hybrid assay system

INVENTOR(S): Becker, Frank; Come, John H.; Kley, Nikolai

PATENT ASSIGNEE(S): Gpc Biotech Ag, Germany; Gpc Biotech Inc.

SOURCE: PCT Int. Appl., 253 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070662	A2	20020912	WO 2002-US6677	20020304
WO 2002070662	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2439263	AA	20020912	CA 2002-2439263	20020304
EP 1364212	A2	20031126	EP 2002-723332	20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005516580	T2	20050609	JP 2002-570690	20020304
US 2004266854	A1	20041230	US 2004-820453	20040407
PRIORITY APPLN. INFO.:			US 2001-272932P	P 20010302
			US 2001-278233P	P 20010323
			US 2001-329437P	P 20011015
			US 2001-336962P	P 20011203

US 2002-91177	A2 20020304
WO 2002-US6677	W 20020304
US 2002-234985	A2 20020903
WO 2002-US33052	A2 20021015
US 2003-460921P	P 20030407
US 2003-531872P	P 20031223


AB The invention concerns compns. and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. In general the invention provides a three hybrid assay system and reagents for the identification of the protein binding partner of a selected small pharmaceutical agent. Likewise, the invention also provides methods and reagents for the identification of a small pharmaceutical agent binding partner of a selected protein. Once detected, the invention further provides methods for monitoring the interaction of the pharmaceutical agent and its protein binding partner that can be used to detect competitors of the interaction.

IT 452913-20-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(three hybrid assay system)

RN 452913-20-1 HCPLUS

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 6 OF 9 USPATFULL on STN

DUPLICATE 3

ACCESSION NUMBER: 2003:232596 USPATFULL

TITLE: Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

INVENTOR(S):  
Bockovich, Nicholas, Malden, MA, UNITED STATES  
Kluge, Arthur, Lincoln, MA, UNITED STATES  
Ram, Siya, Winchester, MA, UNITED STATES  
Wang, Zhonghuo, Lexington, MA, UNITED STATES  
Oalmann, Chris, Waltham, MA, UNITED STATES  
Murthi, Krishna K., Cambridge, MA, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003162797 A1 20030828

US 6753329 B2 20040622

APPLICATION INFO.: US 2002-321284 A1 20021217 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US33052, filed on 15 Oct 2002, PENDING

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2001-336962P 20011203 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA,  
 02110-2624  
 NUMBER OF CLAIMS: 27  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Page(s)  
 LINE COUNT: 1937

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 452913-20-1P

(three hybrid assay system)

RN 452913-20-1 USPATFULL

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2005:105533 USPATFULL  
 TITLE: Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

INVENTOR(S): Bockovich, Nicholas, Malden, MA, UNITED STATES

Kluge, Arthur, Lincoln, MA, UNITED STATES

Ram, Siya, Winchester, MA, UNITED STATES

Wang, Zhongguo, Lexington, MA, UNITED STATES

Oalmann, Chris, Watertown, MA, UNITED STATES

Murthi, Krishna K., Cambridge, MA, UNITED STATES

Becker, Frank, Planegg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): GPC Biotech, Inc, Waltham, MA, UNITED STATES, 02451  
 (U.S. corporation)

GPC Biotech AG, Martinsried/ Munich, GERMANY, FEDERAL REPUBLIC OF, 82152 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005090471 A1 20050428

APPLICATION INFO.: US 2003-492116 A1 20021015 (10)

WO 2002-US33052 20021015

NUMBER DATE

PRIORITY INFORMATION: US 2003-329437P 20011015 (60)  
 US 2003-336962P 20011203 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE  
 INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 1827

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 452913-20-1P

(three hybrid assay system)

RN 452913-20-1 USPATFULL

CN Propanoic acid, 2-[4-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:335759 USPATFULL

TITLE: Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

INVENTOR(S): Bockovich, Nicholas, Malden, MA, UNITED STATES

Kluge, Arthur, Lincoln, MA, UNITED STATES

Oalmann, Chris, Watertown, MA, UNITED STATES

Murthi, Krishna K., Cambridge, MA, UNITED STATES

Ram, Siya, Winchester, MA, UNITED STATES

Wang, Zhongguo, Lexington, MA, UNITED STATES

Huang, Jianxing, N. Billerica, MA, UNITED STATES

PATENT ASSIGNEE(S): GPC Biotech, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2004266853 A1 20041230  
 APPLICATION INFO.: US 2004-819899 A1 20040406 (10)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-460921P	20030407 (60)
	US 2003-531872P	20031223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4149	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 452913-20-1P  
 (three hybrid assay system)  
 RN 452913-20-1 USPATFULL  
 CN Propanoic acid, 2-[4-[(4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L15 ANSWER 9 OF 9 USPATFULL on STN  
 ACCESSION NUMBER: 2003:237716 USPATFULL  
 TITLE: Three hybrid assay system  
 INVENTOR(S): Come, Jon H., Cambridge, MA, UNITED STATES  
 Becker, Frank, Planegg, GERMANY, FEDERAL REPUBLIC OF  
 Kley, Nikolai, Wellesley, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003165873	A1	20030904
APPLICATION INFO.:	US 2002-91177	A1	20020304 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2001-272932P 20010302 (60)  
US 2001-278233P 20010323 (60)  
US 2001-329437P 20011015 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA,  
02110-2624

NUMBER OF CLAIMS: 66  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 22 Drawing Page(s)  
LINE COUNT: 7160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 452913-20-1P

(three hybrid assay system)

RN 452913-20-1 USPATFULL

CN Propanoic acid, 2-[4-[(4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

